Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Medtronic plc NYSE: MDT. In a filing disclosed on May 31st, the Representative disclosed that they had bought between $1,001 and $15,000 in Medtronic stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
- Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
- Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
- Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
- Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
- Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
- Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
- Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.
Medtronic Price Performance
Shares of MDT stock traded up $0.17 during mid-day trading on Wednesday, hitting $85.71. The company had a trading volume of 9,070,616 shares, compared to its average volume of 6,845,407. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39. The stock's 50 day moving average price is $84.04 and its 200-day moving average price is $86.16. Medtronic plc has a 52-week low of $75.96 and a 52-week high of $96.25. The company has a market capitalization of $109.93 billion, a P/E ratio of 26.05, a P/E/G ratio of 2.22 and a beta of 0.81.
Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.58 by $0.04. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The business had revenue of $8.93 billion during the quarter, compared to the consensus estimate of $8.81 billion. During the same quarter in the prior year, the firm earned $1.46 EPS. The business's revenue was up 3.9% on a year-over-year basis. Equities research analysts forecast that Medtronic plc will post 5.46 earnings per share for the current year.
Medtronic Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, June 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.31%. This is a boost from Medtronic's previous quarterly dividend of $0.70. Medtronic's dividend payout ratio (DPR) is presently 78.45%.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered Medtronic from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. Royal Bank of Canada dropped their price target on shares of Medtronic from $105.00 to $101.00 and set an "outperform" rating for the company in a research note on Thursday, May 22nd. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research report on Monday, May 19th. Citigroup upgraded Medtronic from a "neutral" rating to a "buy" rating and boosted their target price for the company from $92.00 to $107.00 in a research report on Tuesday, March 4th. Finally, UBS Group increased their price target on Medtronic from $85.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Medtronic currently has a consensus rating of "Moderate Buy" and an average price target of $97.00.
Read Our Latest Stock Analysis on MDT
Institutional Trading of Medtronic
Several hedge funds have recently modified their holdings of MDT. Vanguard Group Inc. boosted its stake in Medtronic by 0.7% in the first quarter. Vanguard Group Inc. now owns 125,014,241 shares of the medical technology company's stock valued at $11,233,780,000 after acquiring an additional 810,854 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of Medtronic by 1.8% during the 4th quarter. Capital Research Global Investors now owns 33,203,685 shares of the medical technology company's stock valued at $2,652,310,000 after purchasing an additional 571,700 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Medtronic by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 27,056,217 shares of the medical technology company's stock worth $2,155,085,000 after purchasing an additional 574,055 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Medtronic by 7.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 22,278,023 shares of the medical technology company's stock worth $2,001,903,000 after buying an additional 1,461,841 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Medtronic by 3.8% during the 1st quarter. Bank of New York Mellon Corp now owns 20,680,301 shares of the medical technology company's stock valued at $1,858,332,000 after buying an additional 756,192 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About Medtronic
(
Get Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Featured Articles
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
